Brief: Pyxis Oncology Advances Pyx-106 And Pyx-201 Clinical Programs

Pyxis Oncology

30/05/2023 13:50

May 30 (Reuters) - Pyxis Oncology Inc  PYXS.O :
    * PYXIS ONCOLOGY ADVANCES PYX-106 AND PYX-201 CLINICAL
PROGRAMS
    * PYXIS ONCOLOGY INC - FIRST SUBJECT DOSED IN PHASE 1 TRIAL
OF
PYX-106
    * PYXIS ONCOLOGY INC - SECOND DOSE LEVEL INITIATED IN PHASE
1
TRIAL OF PYX-201
    * PYXIS ONCOLOGY INC - PRELIMINARY DATA FROM BOTH TRIALS ON
TRACK
FOR LATE-2023/EARLY-2024 TIMEFRAME

Source text for Eikon:  ID:nGNXtWzrP 
Further company coverage:  PYXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))